6-Day Rally Sends TG Therapeutics Stock Up 28%
TG Therapeutics (TGTX) – a developer of B-cell malignancy drugs and immunotherapies – hit a 6-day winning streak, with cumulative gains over this period amounting to 28%. The company’s market cap has surged by about $1.4 Bil over the last 6 days and currently stands at $6.2 Bil.
Is this an opportunity or a trap? There is not much to fear in TGTX stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell TGTX).
But here is the interesting part. You are reading about this 28% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Is McDonald’s Stock A Trap Or A Missed Opportunity?
- Apple Stock: Alpha Engine Or Portfolio Diversifier?
- Qualcomm’s 70% Rally May Be Just the Start
- McDonald’s Earnings: Global Comps Strong, But Consumer Headwinds Signal Caution
- How Dell Technologies Stock Gained 120%
- Is JNJ Stock Setup For A Rerating?
The following table summarizes the return for TGTX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TGTX | S&P 500 |
|---|---|---|
| 1D | 2.5% | -0.4% |
| 6D (Current Streak) | 28.1% | 2.8% |
| 1M (21D) | 25.8% | 8.2% |
| 3M (63D) | 55.0% | 7.9% |
| YTD 2026 | 44.3% | 7.2% |
| 2025 | -1.0% | 16.4% |
| 2024 | 76.2% | 23.3% |
| 2023 | 44.4% | 24.2% |
However, big gains can follow sharp reversals – but how has TGTX behaved after prior drops? See TGTX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 54 S&P constituents with 3 days or more of consecutive gains and 50 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 35 | 21 |
| 4D | 11 | 9 |
| 5D | 6 | 19 |
| 6D | 2 | 0 |
| 7D or more | 0 | 1 |
| Total >=3 D | 54 | 50 |
Key Financials for TG Therapeutics (TGTX)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $329.0 Mil | $616.3 Mil |
| Operating Income | $41.9 Mil | $123.3 Mil |
| Net Income | $23.4 Mil | $447.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $192.6 Mil | $204.9 Mil |
| Operating Income | $50.5 Mil | $34.8 Mil |
| Net Income | $23.0 Mil | $19.8 Mil |
While TGTX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.